The U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab) for efficacy on October 4, 2016. This regulatory action, identified as BLA 125554 S-16, indicates that new clinical data supporting an expanded or modified use of the drug have been reviewed and accepted by the agency.
Background
Opdivo (nivolumab) is a prescription medication developed and marketed by Bristol Myers Squibb. As an established therapeutic agent, supplemental applications for efficacy are a common mechanism through which pharmaceutical companies can broaden the approved uses of their drugs. These applications are typically supported by new clinical trial data demonstrating the drug's safety and effectiveness for a new indication, a different patient population, or an altered dosing regimen. The FDA's review process for such applications ensures that any proposed new use meets the rigorous standards for efficacy and safety, building upon the drug's existing regulatory profile.
What this means
This supplemental approval for Opdivo (nivolumab) for efficacy on October 4, 2016, signifies an important update to the drug's prescribing information. For clinicians, it means that there is now FDA-backed evidence supporting an additional or refined use of Opdivo, potentially offering new treatment options for specific patient groups. Patients who may benefit from this expanded indication or population will gain access to a new FDA-approved therapeutic strategy. Researchers and patient advocates will find the detailed information in the updated drug label crucial for understanding the specific context and implications of this efficacy approval. It underscores the ongoing development and refinement of approved therapies to address unmet medical needs.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125554 S-16, concerning Opdivo (nivolumab), was recorded on October 4, 2016, on accessdata.fda.gov.